Breast Neoplasms Clinical Trials in Detroit, Michigan

7 studies are recruiting for breast neoplasms in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Karmanos Cancer Center, Detroit, Michigan

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

3. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

   The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07114601 on ClinicalTrials.gov

4. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

5. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

   The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Health ( Site 0002), Detroit, Michigan

   Locations

   259 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312176 on ClinicalTrials.gov

6. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Karmanos Cancer Center - Wayne State University, Detroit, Michigan

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

7. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

   The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) fo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan

   Locations

   295 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06926868 on ClinicalTrials.gov